SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Veys P.)
 

Search: WFRF:(Veys P.) > Myeloablative condi...

  • Willasch, AM (author)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-03-17
  • Springer Science and Business Media LLC,2020

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:143252937
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143252937URI
  • https://doi.org/10.1038/s41409-020-0854-0DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Peters, C (author)
  • Sedlacek, P (author)
  • Dalle, JH (author)
  • Kitra-Roussou, V (author)
  • Yesilipek, A (author)
  • Wachowiak, J (author)
  • Lankester, A (author)
  • Prete, A (author)
  • Hamidieh, AA (author)
  • Ifversen, M (author)
  • Buechner, J (author)
  • Krivan, G (author)
  • Hamladji, RM (author)
  • Diaz-de-Heredia, C (author)
  • Skorobogatova, E (author)
  • Michel, G (author)
  • Locatelli, F (author)
  • Bertaina, A (author)
  • Veys, P (author)
  • Dupont, S (author)
  • Or, R (author)
  • Gungor, T (author)
  • Aleinikova, O (author)
  • Sufliarska, S (author)
  • Sundin, MKarolinska Institutet (author)
  • Rascon, J (author)
  • Kaare, A (author)
  • Nemet, D (author)
  • Fagioli, F (author)
  • Klingebiel, TE (author)
  • Styczynski, J (author)
  • Bierings, M (author)
  • Nagy, K (author)
  • Abecasis, M (author)
  • Afanasyev, B (author)
  • Ansari, M (author)
  • Vettenranta, K (author)
  • Alseraihy, A (author)
  • Chybicka, A (author)
  • Robinson, S (author)
  • Bertrand, Y (author)
  • Kupesiz, A (author)
  • Ghavamzadeh, A (author)
  • Campos, A (author)
  • Pichler, H (author)
  • Dalissier, A (author)
  • Labopin, M (author)
  • Corbacioglu, S (author)
  • Balduzzi, A (author)
  • Galimard, JE (author)
  • Bader, P (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Bone marrow transplantation: Springer Science and Business Media LLC55:98, s. 1540-15511476-53650268-3369

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view